XOMA. has filed a patent for compositions and methods to delay preterm labor in pregnant subjects between 24 to 34 weeks gestation. The method involves administering atosiban and a PGF2a antagonist to improve infant survival by allowing vital organ development. GlobalData’s report on XOMA gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on XOMA, NSAID cancer drugs was a key innovation area identified from patents. XOMA's grant share as of January 2024 was 56%. Grant share is based on the ratio of number of grants to total number of patents.
Method for delaying preterm labor using atosiban and compound
A patent application (Publication Number: US20240024294A1) discloses a method for delaying the onset of delivery in pregnant human subjects by administering therapeutically effective amounts of atosiban and a compound represented by formula (I). The method also includes treating or preventing preterm labor and preventing labor prior to cesarean delivery by administering the same combination of compounds. The compounds are further defined by specific chemical structures and dosages, with the administration route specified as oral for the compound and intravenous for atosiban. The method aims to delay delivery by a specified timeframe following the administration of the compounds, ultimately leading to delivery at a gestational age of at least 34 weeks.
The patent application also includes details about the formulation of the compounds for administration, such as tablets, capsules, gel caps, powders, liquid solutions, or suspensions. Additionally, a kit comprising the compound and atosiban is described, with atosiban formulated for intravenous administration. The kit provides a convenient means for healthcare providers to access and administer the compounds to pregnant individuals at risk of preterm labor or those requiring delayed delivery. The method outlined in the patent application offers a structured approach to managing labor in pregnant individuals, focusing on delaying delivery while ensuring the safety and well-being of both the mother and the fetus.
To know more about GlobalData’s detailed insights on XOMA, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
